Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG

PCX-12

treatment combining radiation therapy with PCX12

Trial Locations (1)

University of Rochester, Rochester

All Listed Sponsors

lead

Haoming (Carl) Qiu

OTHER